Hisamitsu Pharmaceutical Management
Management criteria checks 1/4
Hisamitsu Pharmaceutical's CEO is Kazue Nakatomi, appointed in May 2015, has a tenure of 9.58 years. directly owns 0.33% of the company’s shares, worth ¥999.61M. The average tenure of the management team and the board of directors is 1.4 years and 10.6 years respectively.
Key information
Kazue Nakatomi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.4yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 27
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing
Sep 16Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 20Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00
Jul 26Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 11Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00
Jun 27Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00
Jun 13Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price
Apr 09Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching
Mar 18CEO
Kazue Nakatomi (52 yo)
9.6yrs
Tenure
Mr. Kazuhide Nakatomi, also known as Kazue, serves as Chief Executive Officer since May 2019, President since May 2015 & Director since May 2007 at Hisamitsu Pharmaceutical Co. Inc. and served as its Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.6yrs | no data | 0.33% ¥ 999.6m | |
| Executive VP | less than a year | no data | no data | |
| Exe Officer of Legal Affairs | 10.6yrs | no data | 0.0068% ¥ 20.4m | |
| Executive MD of Human Resources | less than a year | no data | 0.018% ¥ 53.0m | |
| Senior Managing Executive Officer | less than a year | no data | no data | |
| MD, Executive Officer | no data | no data | 0.0095% ¥ 28.5m | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | no data | no data | 0.0082% ¥ 24.5m | |
| Senior Executive Officer & GM of Pharmaceutical Business Division | no data | no data | no data | |
| Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Division | no data | no data | no data | |
| Executive Officer | 3.6yrs | no data | 0.0041% ¥ 12.2m | |
| Senior Executive Officer & GM of MN Business Promotion Office | 1.9yrs | no data | no data | |
| Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Division | less than a year | no data | no data |
1.4yrs
Average Tenure
58.5yo
Average Age
Experienced Management: 4530's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 17.6yrs | no data | 0.33% ¥ 999.6m | |
| Exe Officer of Legal Affairs | 10.6yrs | no data | 0.0068% ¥ 20.4m | |
| Executive MD of Human Resources | 25.6yrs | no data | 0.018% ¥ 53.0m | |
| MD, Executive Officer | 11.6yrs | no data | 0.0095% ¥ 28.5m | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | 10.6yrs | no data | 0.0082% ¥ 24.5m | |
| Executive Officer | 3.6yrs | no data | 0.0041% ¥ 12.2m | |
| Standing Corporate Auditor | 18.6yrs | no data | 0.0027% ¥ 8.2m | |
| Part-time Outside Independent Director | 4.6yrs | no data | 0.0014% ¥ 4.1m | |
| Part-time Outside Independent Director | 4.6yrs | no data | no data | |
| Part Time Outside Corporate Auditor | 1.6yrs | no data | no data | |
| Part Time Outside Independent Director | 1.6yrs | no data | no data |
10.6yrs
Average Tenure
57yo
Average Age
Experienced Board: 4530's board of directors are seasoned and experienced ( 10.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:51 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |